160 related articles for article (PubMed ID: 16264182)
21. Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells.
Bocangel D; Zheng M; Mhashilkar A; Liu Y; Ramesh R; Hunt KK; Chada S
Cancer Gene Ther; 2006 Oct; 13(10):958-68. PubMed ID: 16783343
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein.
Sato S; Kajiyama Y; Sugano M; Iwanuma Y; Sonoue H; Matsumoto T; Sasai K; Tsurumaru M
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):203-11. PubMed ID: 15629613
[TBL] [Abstract][Full Text] [Related]
23. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
Fan YX; Luo RC; Fang YX; Yan X; Lu CW
Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1.
Yu Z; Xia W; Wang HY; Wang SC; Pan Y; Kwong KY; Hortobagyi GN; Hung MC
Mol Carcinog; 2006 Sep; 45(9):667-75. PubMed ID: 16652376
[TBL] [Abstract][Full Text] [Related]
25. Gamma- and delta-tocotrienols exert a more potent anticancer effect than alpha-tocopheryl succinate on breast cancer cell lines irrespective of HER-2/neu expression.
Pierpaoli E; Viola V; Pilolli F; Piroddi M; Galli F; Provinciali M
Life Sci; 2010 Apr; 86(17-18):668-75. PubMed ID: 20188744
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
[TBL] [Abstract][Full Text] [Related]
27. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapy for cancer: the HER-2/neu and Herceptin story.
Ross JS; Gray GS
Clin Leadersh Manag Rev; 2003; 17(6):333-40. PubMed ID: 14692077
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
30. Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu.
Pratesi G; Petrangolini G; Tortoreto M; Addis A; Zunino F; Calcaterra C; Merlo A; Tagliabue E; Menard S; Balsari A
J Immunother; 2008; 31(6):537-44. PubMed ID: 18528301
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
McKenzie T; Liu Y; Fanale M; Swisher SG; Chada S; Hunt KK
Surgery; 2004 Aug; 136(2):437-42. PubMed ID: 15300212
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
[TBL] [Abstract][Full Text] [Related]
33. The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines.
Lyu MA; Kurzrock R; Rosenblum MG
Biochem Pharmacol; 2008 Feb; 75(4):836-46. PubMed ID: 18082672
[TBL] [Abstract][Full Text] [Related]
34. Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu.
Shiu LY; Liang CH; Chang LC; Sheu HM; Tsai EM; Kuo KW
Biosci Rep; 2009 Feb; 29(1):35-45. PubMed ID: 18699774
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
[TBL] [Abstract][Full Text] [Related]
36. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer.
Agus DB; Bunn PA; Franklin W; Garcia M; Ozols RF
Semin Oncol; 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100. PubMed ID: 11236029
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.
Hanna W; Kahn HJ; Trudeau M
Mod Pathol; 1999 Aug; 12(8):827-34. PubMed ID: 10463486
[TBL] [Abstract][Full Text] [Related]
38. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
[TBL] [Abstract][Full Text] [Related]
39. Gamma linolenic acid regulates expression of maspin and the motility of cancer cells.
Jiang WG; Hiscox S; Horrobin DF; Bryce RP; Mansel RE
Biochem Biophys Res Commun; 1997 Aug; 237(3):639-44. PubMed ID: 9299418
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells.
Kominsky SL; Hobeika AC; Lake FA; Torres BA; Johnson HM
Cancer Res; 2000 Jul; 60(14):3904-8. PubMed ID: 10919667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
